Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I just saw your note could you please explain
do you still have shares I do.
okay why was it reinstated
that will be dismissed so buy em up.
when this thing hit silver I am out.
sometimes the shorts lose and this might be the stock which does the trick
A good day for a 000 stock
Why did it go up then?
It is a big world and we will operate somewhere. It is up to each individual state and country. We are making more money and helping more people as time goes on.
Buy on the first up day.
I think that they will make it look like all is lost and the stock price will dip to 5 year low and they will buy and let them off the hook.
I have been in the play for a long time and bought more when it collapsed.
Happy I did.
lol
You told him.
I love a green day
going to test .09s before it is over
only 379000 shares to dollar land.
they are still posting the same old stale news
shorts will cover automatically.
only 550000 shares on market order to dollar land
Skin graphs are not regulated by FDA. Stem cell graphs will prove to be no different.
Good luck to you.
Wow up again.
beautiful chart
Have a Happy Easter
only 350000 shares away from $1.00 on level 2
Description
June 3, 2015
Dear Bioheart Shareholders,
As a public company, Bioheart makes regular detailed reports to the U.S. Securities and Exchange Commission, but while these reports are available to all, they may be too long to be easily read. The following brief summary is offered to make clear the Company’s accomplishments over the past year. Bioheart is a diversified regenerative medicine and cellular therapeutics Company that is making a positive contribution to improving the quality of life for both humans and animals.
Through its four operating business units: Bioheart, US Stem Cell Clinic, US Stem Cell Training and Vetbiologics, the Company is deliveringstate- of-the-art products and services including stem cell collection and processing kits, cell banking and storage, stem cell therapies and physician training services to doctors and patients around the world. Our plan, anchored by sustainable revenue growth and non-dilutive cash flow generation, is to advance our ongoing MyoCell and AdipoCell product candidates to market
while simultaneous working to cure our legacy balance sheetissues.
The following demonstrate the results of our efforts:
* Revenue growth has increased from $96 thousand in 2013 to $1.54 million in 2014 and increased another 25% in the first quarter 2015 quarter over quarter.
* Liabilities were reduced by 20% from December 31, 2013 to December 31, 2014 from $13.4 million to $11.1 million and again reduced an additional $100 thousand in the first quarter of 2015.
* Working capital deficit improved 20% from 2013 to 2014 year over year.
* Net loss was reduced 48% from 2013 to 2014 and remained stable in the first quarter of 2015
* Cash used for operating expenses were reduced 42% from 2013 to 2014 from $1.9 million to $1.1 million year over year.
Our strategic initiatives include, but are not limited to:
* Working toward restarting the MyoCell clinical development program possibly with a
strategicpartner who could augment our manufacturing and clinical capabilities.
* Expanding our clinical pipeline using our AdipoCell technology platform for the
treatmentof rheumatoid arthritis and critical limb ischemia
* Forecasting a 50% increase in sales for our combined US Stem Cell Clinic, Training and
Vetbiologics operations in 2015
* Continuing our debt reduction program
* Re-position our corporate brand
* Implementing an aggressive IR/PR program
* Raising additional capital when advantageous
We remain steadfast in our commitment to our doctors and their patients and to our shareholders and remain confident that our business strategy will continue to produce market and financial
successes. We greatly appreciate your patience and look forward to updating you on our progress.
Sincerely,
William P. Murphy, Jr. M.D. Mike Tomas
Chairman President and Chief Executive Officer
well if revenue goes up I am going to buy more shares every month.
when does earning come out?
200000 share market order takes it over a dime.
Looks like it will test a dime with any increase in revenue or a profit.
Recent news 5 minutes Right to try bill about to pass.
https://www.vox.com/policy-and-politics/2018/3/13/17113690/right-to-try-laws-congress
I am buying 1-2 thousand a month accumulating.
then smack it
it is ready to pop.
That is where I think the fat finger will take the shorts.
People are starting to notice lets see how far USRM runs before squeeze starts.
They can have my shares at 2.00.
Ask getting thin. Going up.
A market order for 150000 will hit in dollar land above 50.00